Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Study suggests wider use of statins and beta-blockers
Statins are typically prescribed to reduce cholesterol, one of the warning signs for heart disease. Beta-blockers are given to patients with high blood pressure, another warning sign for
Statins are typically prescribed to reduce cholesterol, one of the warning signs for heart disease. Beta-blockers are given to patients with high blood pressure, another warning sign for
The FDA also said that it would not approve the drug in an additional indication for smoking cessation. This is another blow for Sanofi although the drug is
Hycamtin is currently indicated for the treatment of metastatic ovarian cancer after failure of initial or subsequent chemotherapy, and for the treatment of small cell lung cancer after
The 58-patient study compared the use of Pfizer’s non-prescription Sudafed (pseudoephedrine hydrochloride) with Merck & Co’s Singulair (montelukast sodium) in the treatment of hay fever and the relief
Schering said that it would exercise an option to buy the US rights to its best-selling Betaseron drug from Chiron. Although Schering currently has a supply agreement with
The European filing for Herceptin follows a similar filing in the US submitted by Genentech, the drug’s inventor. The license applications seek to expand the approved indications for
“Men are 1.5 times more likely to develop Parkinson’s disease than women,” said Dr Eric Vilain, associate professor of human genetics at the David Geffen School of Medicine
Alkermes said that it expects the FDA to classify the response as a “class 1” resubmission, under which the FDA will seek to complete its review within 60
The company presented the data at 2006 Bone Marrow Transplant Meetings in Honolulu, Hawaii. Alkylators like cyclophosphamide and ifosfamide are widely used to prepare people for blood cell
Carboplatin is a generic version of Bristol-Myers Squibb’s ovarian cancer treatment, Paraplatin. Combined sales of the 600mg dosage form by all suppliers exceeded $18.5 million in 2005, the